

Rx Propellant plans Rs 3000 Cr investment to build life sciences lab spaces over next 5 years

19 October 2022 | News

Partnering with Government of Telangana to build state-of-the-art Biopharma accelerator B-hub at Genome Valley, Hyderabad

Rx Propellant, an Actis portfolio company and India's leading life sciences infrastructure and cluster developers, has announced the launch of 9 lac sq ft of lab spaces in Genome Valley, Hyderabad. The foundation stones for two new projects, B-hub and GV1, were laid by KT Rama Rao, Minister for Municipal Administration & Urban Development, Industries & Commerce, and Information Technology, Government of Telangana.

With major footprint in Genome Valley, Rx Propellant has already developed 5 lac sq ft of lab space, most of which are operational with marquee names in life sciences. In total, the current planned development of Rx Propellent at Genome Valley constitutes 7 independent projects namely, Innopolis, Genopolis, Touchstone, ARX, Nextopolis, GV1 and B-hub, spread across 17 lac sq ft.

Commenting on the inauguration, Rama Rao said, "Telangana is home to over 800 Life Sciences companies and our scale makes us major contributors to Global healthcare. Investments such as these will enable faster scale-up of companies to continue charting the growth path, also significantly promoting economic growth in the state."

One of the key projects, B-hub, is a Biopharma accelerator being built in collaboration with Govt. of Telangana to boost the research ecosystem in Genome Valley. Spread across 2 acres, the 1.6 lac sq ft, B-Hub features a fully functional biopharma scale-up manufacturing facility along with a GLP grade turnkey incubator of 40,000 sq ft.

The company has invested Rs 900 crore in development of current life sciences infrastructure and is committed to invest an additional Rs 2000 cr to build a cumulative portfolio over 100 lac sq ft of lab space over the next 5 years across Hyderabad and other major life sciences hubs of India.